Wegovy and abdominal cramps: what the evidence says

What the STEP 1 trial data actually showed about gut symptoms

The STEP 1 trial (a 68-week study of semaglutide 2.4 mg published in the New England Journal of Medicine) found that gastrointestinal side effects were the dominant reason people stopped treatment early. Nausea was the most reported symptom, but abdominal pain, cramping and discomfort featured consistently across the active-treatment group. Importantly, most of these events were mild to moderate and tended to cluster around dose-increase points rather than persisting at a steady plateau throughout treatment.

What the trial also showed is that the intensity of gut symptoms generally falls off as the body adapts. The mechanism is well understood: semaglutide activates GLP-1 receptors in the gut wall as well as the brain, slowing gastric emptying significantly. That slower passage affects gut muscle contractions, the source of most cramping. It is not a sign that something has gone wrong; it is a predictable pharmacological effect. The NHS semaglutide page lists stomach pain explicitly as a common side effect and notes it usually improves as treatment continues.

One practical check you can do in under a minute: run a finger along the lower edge of your ribcage after a meal and note whether the pain is diffuse and dull (typical adjustment cramping) or sharp and localised in one spot. That distinction is worth mentioning to your prescriber or aftercare team if you are unsure.

Why cramps tend to peak after dose increases

Wegovy follows a stepwise titration: the treatment begins at a low dose and moves upward at roughly four-week intervals, with 2.4 mg as the standard maintenance level and 7.2 mg now available as a higher-dose option following MHRA approval in early 2026. Each time the dose increases, the gut slows further and the body needs a fresh adjustment window. Many people who sail through the first few weeks find a later dose step catches them off guard.

The pattern is worth knowing in advance. Cramps that arrive two or three days after moving to a new dose (then gradually ease over one to two weeks) fit the expected profile. Eating smaller portions at each sitting is the single most effective practical adjustment most people report. Spacing meals further apart, staying well hydrated, and cutting back on high-fat foods (which already slow gastric transit independently) all reduce the load on an already slowed gut. If you are thinking about the cost of treatment and whether it is worth pushing through the early side effects, the Wegovy cost page covers what private treatment typically involves and what to weigh up.

For a deeper look at how semaglutide works in the gut and why this titration schedule exists, the semaglutide overview covers the mechanism in plain terms.

Cramps that need medical attention, and the pancreatitis signal

The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known but infrequent complication of GLP-1 medicines including semaglutide. The symptom to take seriously is severe stomach pain that does not ease off, often spreading into the back, sometimes accompanied by vomiting. This is distinct from the generalised cramping most people experience: pancreatitis pain is typically intense, constant, and unlike anything the gut normally produces. It warrants same-day medical assessment, call 111 or go to A&E if the pain is severe.

Gallbladder problems are also more common in people losing weight rapidly, and semaglutide has been associated with an increased rate of gallstones in trials. Upper-right abdominal pain, particularly after eating fatty food, can point to this rather than general GI adjustment. Other symptoms worth reporting promptly include signs of dehydration from severe vomiting or diarrhoea, which can strain the kidneys. Patients can report unexpected side effects through the MHRA Yellow Card scheme, a useful route even for non-emergency observations.

The distinction between adjustment cramping and something requiring attention is not always obvious. Our prescribers at nume offer aftercare seven days a week; if you are uncertain about a symptom pattern, that is exactly the kind of question the aftercare team is there to answer. You can also read more about abdominal pain specifically with Wegovy and how the patterns differ.

Cramps, periods, and leg symptoms, when the cause is not the gut

Not all cramps during Wegovy treatment come from the digestive tract. Some people (particularly women) notice cramping that does not fit a clear post-meal pattern. Period-related cramping, for instance, can intensify or shift timing when body weight changes significantly, and it is easy to attribute this to the medication when the connection is indirect. If cramping seems menstrual in character, Wegovy and period cramps covers what is known about this overlap.

Leg cramps are a separate, occasionally reported complaint that may relate to changes in fluid intake, electrolyte balance, or the reduced dietary variety some people experience when appetite falls sharply. These are not typically a pharmacological effect of semaglutide itself. A page specifically on leg cramps during Wegovy treatment goes into more detail. For a broader look at cramping patterns across semaglutide use, the semaglutide and cramps page and the cramps on Wegovy guide both add useful context depending on what you are experiencing.

If you are considering starting Wegovy and want to speak to a prescriber about how your personal health picture fits, you can speak to our prescribers through a free consultation, the same day, with no waiting list.